Manufacturer
Ascend Laboratories, LLC
105 drugs, 270 product strengths, 51 recalls on record.
Drugs Ascend Laboratories, LLC makes
Atorvastatin+2.4%Generic · 50 makersPharmacies pay from$0.699 open recallsAmlodipine-2.6%Generic · 33 makersPharmacies pay from$0.3017 open recallsGabapentin+4.5%Generic · 72 makersPharmacies pay from$0.667 open recallsRosuvastatin-1.4%Generic · 35 makersPharmacies pay from$0.954 open recallsVenlafaxine+0.3%Generic · 49 makersPharmacies pay from$2.14Clopidogrel-0.6%Generic · 33 makersPharmacies pay from$1.411 open recallMethylphenidate-1.0%Generic · 28 makersPharmacies pay from$3.65Unavailable1 open recallQuetiapine+3.8%Generic · 37 makersPharmacies pay from$0.63Pregabalin+5.4%Generic · 38 makersPharmacies pay from$1.341 open recallAripiprazole+6.2%Generic · 42 makersPharmacies pay from$3.503 open recallsRivaroxaban-3.6%Generic · 17 makersPharmacies pay from$18.80Being discontinuedDapagliflozin+0.3%Generic · 18 makersPharmacies pay from$4.89Finasteride-0.3%Generic · 30 makersPharmacies pay from$1.312 open recallsEsomeprazole-3.4%Generic · 107 makersPharmacies pay from$3.844 open recallsSildenafil+2.3%Generic · 54 makersPharmacies pay from$1.572 open recallsVarenicline+12.1%Generic · 22 makersPharmacies pay from$8.611 open recallIbuprofen+1.5%Generic · 240 makersPharmacies pay from$1.019 open recallsMetformin+2.2%Generic · 65 makersPharmacies pay from$0.44Being discontinued21 open recallsMetoprolol+1.0%Generic · 65 makersPharmacies pay from$0.48Being discontinued9 open recallsTamsulosin-2.1%Generic · 38 makersPharmacies pay from$1.47Famotidine-2.3%Generic · 123 makersPharmacies pay from$0.612 open recallsDiclofenac-1.0%Generic · 150 makersPharmacies pay from$1.89Being discontinued4 open recallsDuloxetine-3.0%Generic · 32 makersPharmacies pay from$2.9844 open recallsTopiramate+1.5%Generic · 36 makersPharmacies pay from$0.82Tizanidine+2.2%Generic · 41 makersPharmacies pay from$0.972 open recallsValsartan-0.3%Generic · 26 makersPharmacies pay from$2.42Being discontinued54 open recallsCephalexin-2.7%Generic · 31 makersPharmacies pay from$2.708 open recallsLevetiracetam-1.9%Generic · 63 makersPharmacies pay from$1.702 open recallsOlmesartan+0.3%Generic · 21 makersPharmacies pay from$1.83Chlorthalidone-1.6%Generic · 31 makersPharmacies pay from$2.193 open recallsEzetimibe+5.6%Generic · 23 makersPharmacies pay from$2.11Nifedipine+0.4%Generic · 27 makersPharmacies pay from$3.28Oxcarbazepine+2.8%Generic · 35 makersPharmacies pay from$3.201 open recallLansoprazole+1.7%Generic · 57 makersPharmacies pay from$3.131 open recallRizatriptan-2.2%Generic · 14 makersPharmacies pay from$9.846 open recallsMesalamine-5.0%Generic · 33 makersPharmacies pay from$14.52Being discontinued1 open recallBenzonatate-6.1%Generic · 35 makersPharmacies pay from$1.851 open recallTriamcinolone-0.9%Generic · 70 makersPharmacies pay from$0.67In shortage15 open recallsMirabegron-2.6%Generic · 6 makersPharmacies pay from$1741 open recallTicagrelor-4.0%Generic · 21 makersPharmacies pay from$7.29Colchicine-2.6%Generic · 30 makersPharmacies pay from$3.57Sacubitril / valsartan-2.0%Generic · 19 makersPharmacies pay from$15.06Lidocaine-1.8%Generic · 396 makersPharmacies pay from$1.74Unavailable59 open recallsLacosamide+0.3%Generic · 48 makersPharmacies pay from$3.626 open recallsTobramycin-1.1%Generic · 42 makersPharmacies pay from$5.48Being discontinued6 open recallsMycophenolate mofetil-3.9%Generic · 33 makersPharmacies pay from$4.042 open recallsEnalapril+16.7%Generic · 29 makersPharmacies pay from$1.885 open recallsTacrolimus+4.1%Generic · 25 makersPharmacies pay from$3.583 open recallsVancomycinNo changeGeneric · 25 makersPharmacies pay from$23.05Being discontinued24 open recallsLurasidone+2.6%Generic · 22 makersPharmacies pay from$4.36Cefdinir-2.8%Generic · 24 makersPharmacies pay from$6.46Morphine+0.1%Generic · 17 makersPharmacies pay from$6.32Unavailable7 open recallsLinezolid+2.3%Generic · 23 makersPharmacies pay from$44.22Azelastine-2.4%Generic · 22 makersPharmacies pay from$5.842 open recallsFingolimod-9.9%Generic · 21 makersPharmacies pay from$42.681 open recallNebivolol+1.7%Generic · 18 makersPharmacies pay from$3.43Being discontinued2 open recallsTelmisartan+9.1%Generic · 20 makersPharmacies pay from$3.29Dexmethylphenidate+13.0%Generic · 12 makersPharmacies pay from$5.67Minocycline-2.3%Generic · 17 makersPharmacies pay from$5.481 open recallRabeprazole+4.1%Generic · 20 makersPharmacies pay from$6.99Ranolazine+0.9%Generic · 19 makersPharmacies pay from$4.993 open recallsTemazepam-1.5%Generic · 18 makersPharmacies pay from$2.19Sirolimus-1.4%Generic · 17 makersPharmacies pay from$21.381 open recallCefuroxime-2.0%Generic · 17 makersPharmacies pay from$8.221 open recallBrivaracetam-2.3%Generic · 13 makersPharmacies pay from$5.17Clobazam+5.3%Generic · 15 makersPharmacies pay from$7.313 open recallsMethadone+2.7%Generic · 16 makersPharmacies pay from$4.951 open recallAzathioprine+3.1%Generic · 15 makersPharmacies pay from$3.85Capecitabine-0.4%Generic · 16 makersPharmacies pay from$10.85Colesevelam+1.1%Generic · 15 makersPharmacies pay from$7.931 open recallCholestyramine resin+8.3%Generic · 14 makersPharmacies pay from$181Dabigatran etexilate+0.7%Generic · 13 makersPharmacies pay from$21.469 open recallsFamotidine / ibuprofen+3.2%Generic · 15 makersPharmacies pay from$22.091 open recallRoflumilast-2.8%Generic · 13 makersPharmacies pay from$9.07Cinacalcet+1.8%Generic · 13 makersPharmacies pay from$12.5720 open recallsDimethyl fumarate-3.0%Generic · 14 makersPharmacies pay from$11.45Hydrochlorothiazide / olmesartan-4.9%Generic · 13 makersPharmacies pay from$4.92Brompheniramine / dextromethorphan / pseudoephedrine+0.4%Generic · 14 makersPharmacies pay from$8.08Deferasirox-10.3%Generic · 13 makersPharmacies pay from$33.581 open recallMycophenolic acid-2.3%Generic · 12 makersPharmacies pay from$3.071 open recallSolifenacin-9.8%Generic · 13 makersPharmacies pay from$3.832 open recallsVigabatrinGeneric · 14 makersNo weekly priceBeing discontinuedItraconazole-6.8%Generic · 12 makersPharmacies pay from$25.46Being discontinuedRasagiline+7.6%Generic · 12 makersPharmacies pay from$13.80Rufinamide+4.4%Generic · 11 makersPharmacies pay from$27.721 open recallAmlodipine / olmesartan+7.5%Generic · 10 makersPharmacies pay from$7.054 open recallsChlordiazepoxide / clidinium+7.8%Generic · 12 makersPharmacies pay from$8.28Magnesium sulfate / potassium sulfate / sodium sulfate-1.6%Generic · 11 makersPharmacies pay from$31.39EverolimusNo changeGeneric · 8 makersPharmacies pay from$50.66Being discontinued5 open recallsEslicarbazepine+5.5%Generic · 8 makersPharmacies pay from$45.61Cefpodoxime+3.2%Generic · 9 makersPharmacies pay from$32.00Dapagliflozin / metformin+13.2%Generic · 7 makersPharmacies pay from$14.61Fosfomycin+0.6%Generic · 10 makersPharmacies pay from$26.372 open recallsTemozolomideNo changeGeneric · 9 makersPharmacies pay from$26.391 open recallDalfampridine-8.2%Generic · 9 makersPharmacies pay from$11.00Droxidopa-0.6%Generic · 8 makersPharmacies pay from$14.09Cefprozil-10.5%Generic · 7 makersPharmacies pay from$9.24Fesoterodine+5.4%Generic · 7 makersPharmacies pay from$23.302 open recallsSilver sulfadiazine+0.2%Generic · 8 makersPharmacies pay from$13.01Ezetimibe / simvastatin-3.3%Generic · 5 makersPharmacies pay from$5.541 open recallCefixime+1.8%Generic · 6 makersPharmacies pay from$122Lanthanum carbonate-1.9%Generic · 6 makersPharmacies pay from$93.444 open recallsTolvaptan-19.2%Generic · 6 makersPharmacies pay from$353Dronabinol-2.6%Generic · 5 makersPharmacies pay from$98.01Riluzole-0.7%Generic · 5 makersPharmacies pay from$8.74Unavailable
Recalls
Class IIOngoingOct 28, 2026Amlodipine and Olmesartan Medoxomil TabletsOut of specification due to dissolution.Ascend Laboratories, LLC · D-0045-2027Class IIIOngoingAug 5, 2026Dabigatran Etexilate CapsulesFailed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month...Ascend Laboratories, LLC · D-0737-2026Class IIIOngoingAug 5, 2026Dabigatran Etexilate CapsulesFailed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month...Ascend Laboratories, LLC · D-0738-2026Class IIIOngoingAug 5, 2026Dabigatran Etexilate CapsulesFailed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month...Ascend Laboratories, LLC · D-0739-2026Class IIOngoingJul 29, 2026Amlodipine and Olmesartan Medoxomil TabletsFailed Dissolution Specifications; Olmesartan Medoxomil content below specificationsAscend Laboratories, LLC · D-0712-2026Class IIIOngoingJul 29, 2026Dabigatran etexilate CapsulesFailed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total...Ascend Laboratories, LLC · D-0735-2026Class IIIOngoingJul 29, 2026Dabigatran etexilate CapsulesFailed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total...Ascend Laboratories, LLC · D-0736-2026Class IIOngoingJun 17, 2026Minocycline Hydrochloride Extended-Release TabletsFailed Dissolution Specifications: An out-of-specification (OOS) result was observed during the 9th month of dissolution test analysisAscend Laboratories, LLC · D-0597-2026Class IIOngoingJun 10, 2026Amlodipine and Olmesartan Medoxomil TabletsFailed Dissolution Specifications: Olmesartan Medoxomil content below specificationsAscend Laboratories, LLC · D-0556-2026Class IIOngoingMay 20, 2026Ascend LaboratoriesFailed Dissolution SpecificationsAscend Laboratories, LLC · D-0547-2026Class IIOngoingOct 22, 2025Atorvastatin Calcium Tablets USPFailed Dissolution SpecificationsAscend Laboratories, LLC · D-0017-2026Class IIOngoingOct 22, 2025Atorvastatin Calcium Tablets USPFailed Dissolution SpecificationsAscend Laboratories, LLC · D-0018-2026Class IIOngoingOct 22, 2025Atorvastatin Calcium Tablets USPFailed Dissolution SpecificationsAscend Laboratories, LLC · D-0019-2026Class IIOngoingOct 22, 2025Atorvastatin Calcium Tablets USPFailed Dissolution SpecificationsAscend Laboratories, LLC · D-0020-2026Class IIOngoingSep 24, 2025Aripiprazole TabletsSuperpotent drugAscend Laboratories, LLC · D-0645-2025Class IIOngoingAug 20, 2025Amlodipine and Olmesartan Medoxomil TabletsFailed Dissolution Specifications: low dissolution resultsAscend Laboratories, LLC · D-0576-2025Class IIOngoingJul 23, 2025Rizatriptan Benzoate TabletsCGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.Ascend Laboratories, LLC · D-0533-2025Class IIOngoingJul 23, 2025Rizatriptan Benzoate TabletsCGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.Ascend Laboratories, LLC · D-0534-2025Class IIOngoingJun 18, 2025Cephalexin for Oral SuspensionFailed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The...Ascend Laboratories, LLC · D-0468-2025Class IIOngoingJun 18, 2025Cephalexin for Oral SuspensionFailed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The...Ascend Laboratories, LLC · D-0469-2025Class IIOngoingDec 18, 2024Dabigatran EtexilateCGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limitAscend Laboratories, LLC · D-0129-2025Class IIOngoingDec 18, 2024Dabigatran EtexilateCGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limitAscend Laboratories, LLC · D-0130-2025Class IIOngoingOct 2, 2024Mycophenolic Acid Delayed-Release Tablets USPFailed Dissolution SpecificationsAscend Laboratories, LLC · D-0668-2024Class IIOngoingFeb 28, 2024Fosfomycin Tromethamine Granules for Oral SolutionFailed Impurities/Degradation Specification: Out of specification for organic impuritiesAscend Laboratories, LLC · D-0339-2024Class IIOngoingJan 24, 2024Ibuprofen and Famotidine Tablets 800mg/26.6mgPresence of Foreign Tablet/Capsule: A stray Rasagiline Mesylate 1 mg tablet was discovered in an unopened bottle of Ibuprofen and Famotidine.Ascend Laboratories, LLC · D-0237-2024Class IIITerminatedSep 13, 2023Fosfomycin Tromethamine Granules for Oral SolutionFailed Impurities/Degradation Specifications: Out-of-specification results observed for the organic impurities test at 6 months, RT Stability.Ascend Laboratories, LLC · D-1145-2023Class IIOngoingJul 26, 2023Fingolimod CapsulesFailed Dissolution SpecificationsAscend Laboratories, LLC · D-0925-2023Class IIOngoingApr 26, 2023Aripiprazole TabletsOut of specification (OOS) for Spectroscopic Identification test by IR.Ascend Laboratories, LLC · D-0539-2023Class IIOngoingApr 5, 2023Dabigatran Etexilate 150mg CapsulesCGMP Deviations: Detection of N-nitroso-dabigatran (NDAB) impurity levels above the Acceptable Daily Intake Limit.Ascend Laboratories, LLC · D-0534-2023Class IIOngoingApr 5, 2023Dabigatran Etexilate CapsulesCGMP Deviations: Detection of N-nitroso-dabigatran (NDAB) impurity levels above the Acceptable Daily Intake Limit.Ascend Laboratories, LLC · D-0533-2023
About Ascend Laboratories, LLC
No comments yet. Questions, tips, what worked for you - start the conversation.